Malignant Lymphomas – Past, Present and Future

Česká verzia

Authors: M. Trněný; P. Klener Jr.; R. Pytlík
Authors place of work: I. interní klinika – klinika hematologie 1. LF UK a VFN v Praze
Published in the journal: Klin Onkol 2015; 28(Supplementum 3): 55-63
doi: https://doi.org/10.14735/amko20153S55

Summary

This review summarizes the key steps on the way to understanding lymphoma biology and management. The history of lymphomas started in 1832 when Thomas Hodgkin first presented lymphomas. Classification of lymphoproliferative tumors has changed almost every 10 years as a reflection of deeper knowledge of this disease. Systemic therapy has developed in several steps starting by monotherapy with different chemotherapeutic agents, followed by the era of combination chemotherapy and by the rituximab era, which significantly changed the treatment paradigm. Several years ago, we entered into the fourth era characterized by many different targeted treatments. Radiotherapy remains an important part of lymphoma management. Lymphoproliferative tumors incidence is growing but mortality has started to decline starting in the year 2000 as the reflection of targeted therapy based on biology and pathogenesis.

Key words:
lymphoma – classification – chemotherapy − targeted therapy

This study was supported by grants of Internal Grant Agency of the Czech Ministry of Health No. NT13072-4/2012 a NT12193-5/2011 and PRVOUK-27/LF1/1.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
1. 10. 2015

Accepted:
3. 10. 2015

Zdroje

1. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans 1832; 17: 69– 97.

2. Hicks EB, Rappaport H, Winter WJ. Follicular lymphoma; a re‑evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 1956; 9(4): 792– 821.

3. Rappaport H. Tumors of the Hamatopoietic systems. In: Atlas of Tumor Pathology. Armed Forces Institute of Pathology, 1966.

4. Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer 1974; 34 (Suppl 4): 1488– 1503.

5. Bennett M, Farrer‑ Brown G, Henry K et al. Classification of non‑Hodgkin‘s lymphomas. Lancet 1974; 304(7877): 405– 408.

6. Lennert K. Morphology and classification of malignant lymphomas and so‑ called reticuloses. Acta Neuropathol Suppl 1975; Suppl 6: 1– 16.

7. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(5517): 495– 497.

8. National Cancer Institute sponsored study of classifications of non‑Hodgkin‘s lymphomas: summary and description of a working formulation for clinical usage. The Non‑ Hodgkin‘s Lymphoma Pathologic Classification Project. Cancer 1982; 49(10): 2112– 2135.

9. Harris NL, Jaffe ES, Stein H et al. A revised European‑ American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84(5): 1361– 1392.

10. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B‑ cell lymphoma identified by gene expression profiling. Nature 2000; 403(6769): 503– 511.

11. World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissue. Lyon: IARC Press 2001.

12. Swerdlow SH, Campo E, Harris NL et al (eds). WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press 2008.

13. Mamessier E, Broussais‑ Guillaumot F, Chetaille B et al. Nature and importance of follicular lymphoma precursors. Haematologica 2014; 99(5): 802– 810. doi: 10.3324/ haematol.2013.085548.

14. De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol 2015; 15(3): 137– 148. doi: 10.1038/ nri3804.

15. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352(8): 804– 815.

16. Jiang Y, Hatzi K, Shaknovich R. Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood 2013; 121(21): 4271– 4279. doi: 10.1182/ blood‑ 2012‑ 12‑ 451799.

17. Jiang Y, Melnick A. The epigenetic basis of diffuse large B‑ cell lymphoma. Semin Hematol 2015; 52(2): 86– 96. doi: 10.1053/ j.seminhematol.2015.01.003.

18. Ame‑ Thomas P, Tarte K. The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity. Semin Cancer Biol 2014; 24: 23– 32. doi: 10.1016/ j.semcancer.2013.08.001.

19. Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 2014; 14(8): 517– 534. doi: 10.1038/ nrc3774.

20. Gloghini A, Dolcetti R, Carbone A. Lymphomas occurr-ing specifically in HIV‑ infected patients: from pathogenesis to pathology. Semin Cancer Biol 2013; 23(6): 457– 467. doi: 10.1016/ j.semcancer.2013.08.004.

21. Al‑ Mansour Z, Nelson BP, Evens AM. Post‑transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep 2013; 8(3): 173– 183. doi: 10.1007/ s11899‑ 013‑ 0162‑ 5.

22. De Paoli P, Carbone A. Microenvironmental abnormalities induced by viral cooperation: Impact on lymphomagenesis. Semin Cancer Biol 2015; 34: 70– 80. doi: 10.1016/ j.semcancer.2015.03.009.

23. Altieri A, Bermejo JL, Hemminki K. Familial risk for non‑Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family‑ Cancer Database. Blood 2005; 106(2): 668– 672.

24. Goldin LR, Bjorkholm M, Kristinsson SY et al. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol 2009; 146(1): 91– 94. doi: 10.1111/ j.1365‑ 2141.2009.07721.x.

25. Uzis.cz [internetová stránka]. Ústav zdravotnických informací a statistiky. Novotvary. Dostupné z: http:/ / www.uzis.cz/ katalog/ zdravotnicka‑ statistika/ novotvary.

26. Cheson BD, Fisher RI, Barrington SF et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non‑Hodgkin lymphoma: the Lugano classification. J ClinOncol 2014; 32(27): 3059– 3068.

27. Barrington SF, Mikhaeel NG, Kostakoglu L et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32(27): 3048– 3058.

28. Pusey W. Cases of sarcoma and Hodgkin’s disease treated by exposures to X‑ray – a preliminary report. JAMA 1902; 38(3): 166– 169.

29. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009; 27(9): 1492– 1501. doi: 10.1200/ JCO.2008.18.7252.

30. Ozegowski W, Krebs D. w‑ [bis‑ (chlorethyl)– amino‑ benzimidazolyl‑ (2)]– propionic or butyric acids as potential cytostatic agents. J Prakt Chem 1963; 20: 178– 186.

31. Lowenbraun S, DeVita VT, Serpick AA. Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma. Cancer 1970; 25(5): 1018– 1025.

32. Bonadonna G, Zucali R, Monfardini S et al. Combination chemotherapy of Hodgkin‘s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36(1): 252– 259.

33. Gottlieb JA, Gutterman JU, McCredie KB et al. Chemotherapy of malignant lymphoma with adriamycin. Cancer Res 1973; 33(11): 3024– 3028.

34. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non‑Hodgkin‘s lymphoma. N Engl J Med 1993; 328(14): 1002– 1006.

35. Tilly H, Lepage E, Coiffier BA et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor‑ prognosis aggressive non‑Hodgkin lymphoma. Blood 2003; 102(13): 4284– 4289.

36. Récher C, Coiffier B, Haioun C et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B‑ cell lymphoma (LNH03- 2B): an open‑ label randomised phase 3 trial. Lancet 2011; 378(9806): 1858– 1867. doi: 10.1016/ S0140‑ 6736(11)61040‑ 4.

37. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased‑dose BEACOPP chemotherapy compared with COPP‑ ABVD for advanced Hodgkin‘s disease. N Engl J Med 2003; 348(24): 2386– 2395.

38. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single‑dose infusion of chimeric anti‑CD20 monoclonal antibody (IDEC‑ C2B8) in patients with recurrent B‑ cell lymphoma. Blood 1994; 84(8): 2457– 2466.

39. McLaughlin P, Grillo L, Link BK et al. Rituximab chimeric anti‑CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four‑dose treatment program. J Clin Oncol 1998; 16(8): 2825– 2833.

40. Nadler LM, Stashenko P, Hardy R et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma‑associated antigen. Cancer Res 1980; 40(9): 3147– 3154.

41. Coiffier B, Lepage E, Herbrecht R et al. MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B‑ cell lymphoma (DLCL): intermi results of a randomized GELA trial. Blood 2000; 96 (Suppl 1):950– 950.

42. Goede V, Fischer K, Busch R et al. Obinutuzumab plus Chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370(12): 1101– 1110. doi: 10.1056/ NEJMoa1313984.

43. Morschhauser F, Radford J, Van Hoof A et al. Phase III trial of consolidation therapy with yttrium‑ 90- ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26(32): 5156– 5164. doi: 10.1200/ JCO.2008.17.2015.

44. Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin‘s lymphoma. J Clin Oncol 2012; 30(18): 2183– 2189. doi: 10.1200/ JCO.2011.38.0410.

45. Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN‑ 35) in patients with relapsed or refractory systemic anaplastic large‑ cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30(18): 2190– 2196. doi: 10.1200/ JCO.2011.38.0402.

46. Topp MS, Gokbuget N, Stein AS et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B‑ precursor acute lymphoblastic leukaemia: a multicentre, single‑arm, phase 2 study. Lancet Oncol 2015; 16(1): 57– 66. doi: 10.1016/ S1470‑ 2045(14)71170‑ 2.

47. Viardot A, Goebeler M, Hess G et al. Treatment of relapsed/ refractory diffuse large B‑ cell lymphoma with the bispecific T‑ cell engager (BiTE®) antibody construct blinatumomab: primary analysis results from an open‑ label, phase 2 study. Blood 2014; 124(21): 4460– 4460.

48. Rothe A, Sasse S, Topp MS et al. A phase 1 study of the bispecific anti‑CD30/ CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 2015; 125(26): 4024– 4031. doi: 10.1182/ blood‑ 2014‑ 12‑ 614636.

49. Reeder CB, Ansell SM. Novel therapeutic agents for B‑ cell lymphoma: developing rational combinations. Blood 2011; 117(5): 1453– 1462. doi: 10.1182/ blood‑ 2010‑ 06‑ 255067.

50. Perez‑ Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117(1): 26– 38. doi: 10.1182/ blood‑ 2010‑ 04‑ 189977.

51. Wang ML, Rule S, Martin P et al. Targeting BTK with ibrutinib in relapsed or refractory mantle‑ cell lymphoma. N Engl J Med 2013; 369(6): 507– 516. doi: 10.1056/ NEJMoa1306220.

52. Byrd JC, Brown JR, O‘Brien S et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371(3): 213– 223. doi: 10.1056/ NEJMoa1400376.

53. Wilson WH, Young RM, Schmitz R et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015; 21(8): 922– 926.

54. Flinn I, Kimby E, Cotter FE et al. A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS‑ 1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL). ASCO Meeting Abstracts 2013; 31 (Suppl 15): TPS7131.

55. Gopal AK, Kahl BS, de Vos S et al. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370(11): 1008– 1018. doi: 10.1056/ NEJMoa1314583.

56. Seymour J, Davids MS, Pagel JM et al. Bcl‑ 2 Inhibitor ABT‑ 199 (GDC‑ 0199) monotherapy shows anti‑tumor activity including complete remissions in high‑risk relapsed/ refractory (R/ R) chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL). Blood 2013; 122(21): 872– 872.

57. Fowler NH, Davis RE, Rawal S et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open‑ label, phase 2 trial. Lancet Oncol 2014; 15(12): 1311– 1318. doi: 10.1016/ S1470‑ 2045(14)70455‑ 3.

58. Wang M, Fowler N, Wagner‑ Bartak N et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013; 27(9): 1902– 1909. doi: 10.1038/ leu.2013.95.

59. Trneny M, Lamy T, Walewski J et al. Phase II randomized, multicenter study of lenalidomide vs best investigator’s choice in relapsed/ refractory mantle cell lymphoma: results of the MCL‑ 002 (SPRINT) study. Blood 2014; 124(21): 626.

60. Vitolo U, Chiappella A, Franceschetti S et al. Lenalidomide plus R‑ CHOP21 in elderly patients with untreated diffuse large B‑ cell lymphoma: results of the REAL07 open‑ label, multicentre, phase 2 trial. Lancet Oncol 2014; 15(7): 730– 737. doi: 10.1016/ S1470‑ 2045(14)70191‑ 3.

61. Ansell SM, Lesokhin AM, Borrello I et al. PD‑ 1 blockade with nivolumab in relapsed or refractory Hodgkin‘s lymphoma. N Engl J Med 2015; 372(4): 311– 319. doi: 10.1056/ NEJMoa1411087.

62. Moskowitz CH, Ribrag V, Michot JM et al. PD‑ 1 Blockade with the monoclonal antibody pembrolizumab (MK‑ 3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE‑ 013). Blood 2014; 124(21): 290.

63. Westin JR, Chu F, Zhang M et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open‑ label, phase 2 trial. Lancet Oncol 2014; 15(1): 69– 77. doi: 10.1016/S1470‑ 2045(13)70551‑ 5.